

## Research Activities Newsletter

---

April 2023

### In the News: Congratulations to the following awardees!!




**Katherine Balantekin**, Assistant Professor of Exercise and Nutrition Sciences received a continuation award from the National Institute of Diabetes and Digestive and Kidney Diseases/NIH for the project entitled, *The Intersection between Loss of Control Eating and Obesity: The Role of Restriction and Food Reinforcement*. The project will continue to explore the relationships among LOC eating, parental restriction, and the reinforcing value of food in a sample of 7–10-year-old children at risk for obesity.



**Kaelyn Burns**, PhD candidate in the Department of Epidemiology and Environmental Health (EEH), is the PI and trainee on an F-31 award from the National Heart, Lung, and Blood Institute/NIH entitled, *Application of a Novel Dietary Pattern Predictive of Trimethylamine N-oxide Production to Examine Associations with Metabolomic Profiles, the Gut Microbiome, and Vascular Health*. **Amy Millen**, Associate Professor in EEH, **Rachael Hageman Blair**, Associate Professor in Biostatistics, **Michael LaMonte**, Research Professor in EEH and **Jean Wactawski-Wende**, SUNY Distinguished Professor in EEH and the SPHHP Dean, are her Faculty Sponsors. The study is to clarify the interplay among dietary intake, metabolism, the gut microbiome, and vascular health by examining associations among a novel dietary pattern predictive of biomarkers of TMAO production with metabolomic profiles, the gut microbiome composition, and retinal vessel caliber.



**Gregory Homish**, Professor and Chair of the Department of Community Health and Health Behavior is Co-PI (with Co-PI: Ken Leonard, Psychiatry) on a continuation award from the National Institute on Alcohol Abuse and Alcoholism/NIH, for the T32-training grant entitled *Research Training on Alcohol Etiology and Treatment*.



**Heather Orom**, Associate Professor in CHHB and SPHHP Associate Dean for Equity, Diversity and Inclusion, is a member of the training committee. Established in 2000, the interdisciplinary training program provides postdoctoral and predoctoral trainees with research training related to alcohol problems.



**Jeffrey Miecznikowski**, Associate Professor and Interim Chair of the Department of Biostatistics, is Co-I on a continuation award from the National Institute of Dental & Craniofacial Research/NIH (PI: Jill Kramer, Oral Biology) for the project entitled, *Analysis of MyD88-mediated Immune Activation in Sjogrens Syndrome Pathogenesis*. This project will continue to discover novel pathways that can be targeted to treat pSS and other autoimmune diseases.



**Ekaterina Noyes**, Professor of Epidemiology and Environmental Health and SPHHP Associate Dean for Translational and Team Science is Co-I on a continuation award from the Agency for Healthcare Research and Quality (PI: Sharon Hewner, Nursing) for the project entitled, *Implementing Personalized Cross-sector Transitional Care Management to Promote Care Continuity, Reduce Low Value Utilization, and Reduce the Burden of Treatment for High-need, High-cost Patients* (HNHC). The project will continue to study whether identifying HNHC patients at the point of transition between care settings, coupled with enhanced communication through an interoperable shared care plan, will facilitate referrals to care management, improve continuity, and reduce reliance on low-value care.



**Riana Pryor**, Assistant Professor of Exercise and Nutrition Sciences, is PI on a continuation award from the Centers for Disease Control and Prevention for the research project entitled, *Short- and Long-term Health Consequences of Workers During Consecutive Days of Heat Stress*. The study will provide data to inform NIOSH’s recommendations for mitigating fatigue and meeting long-term health needs of workers during consecutive days of heat stress.



**Gregory Wilding**, Professor and former Chair of Biostatistics, is Co-I on a continuation award from the National Institute of Allergy and Infectious Diseases/NIH (PI: Jonathan Lovell, Biomedical Engineering) for the project entitled, *Developing a Multi-Valent Subunit Particle Vaccine Against Tuberculosis*. The project will continue to design a vaccine with TB antigens using a next-generation adjuvant system and will benchmark the vaccine against the established BCG vaccine.

**Congratulations to the SPHHP faculty who received pilot funding awards from internal sources (SPHHP, UB’s VPRED and RF-SUNY).**

**Recipients of awards from the SPHHP Pilot Funding Program - December 2022 deadline**



Rachel Hageman Blair is PI for the research project entitled, *Network-based Optimization of Saccharomyces Cerevisiae Pathways for Terpenoid Production*.



Lucia Leone is PI for the research project entitled, *Piloting a Campus Mobile Market to Address Food Insecurity Among University at Buffalo Students*.



Michael LaMonte is PI for the research project entitled, *blood biomarkers of Hemostasis and Endothelial Function in Relation to Proton Pump Inhibitor Use and Frailty in Older Women: A Pilot Study*.




Meng Wang is PI for the research project entitled, *Reducing Health Impacts of Airborne Exposure to Traffic Air Pollution and Virus Transmission: An Intervention Study on Bus Drivers*.

**Recipient of funding from UB’s Office of the Vice President for Research and Economic Development**



Lina Mu is PI for the research project entitled, *Air Pollution Exposure, Physical Activity, and Cardiovascular Health*. Given the limits on the VPRED’s funding, Dr. Mu also received some funding from the SPHHP’s pilot funding program.

**Recipient of funding from RF SUNY**



Heather Orom is PI for the research project entitled, *Interventions to Decrease Cancer Information Avoidance*.

## ***In This Issue***

<b>In the News: Congratulations to the Following Awardees .....</b>	<b>1</b>
<b>Grant Clinic.....</b>	<b>3</b>
<b>NIH Funding Opportunities</b>	
<b>Request for Applications (RFA) .....</b>	<b>5</b>
<b>Program Announcements Reviews in an Institute (PAR) .....</b>	<b>10</b>
<b>UB Funding Opportunities.....</b>	<b>14</b>
<b>Words to Live By.....</b>	<b>14</b>

## **Grant Clinic**



### **Data Management and Sharing Plan vs. Resource Sharing Plan**

By [NIH Staff](#)

Posted March 20, 2023

The Data Management and Sharing (DMS) Plan and Resource Sharing Plan are separate attachments that may be required for your application. One does not necessarily replace the other.

NIH has a number of sharing policies. The Data Management and Sharing and Genomic Data Sharing Policies have been hot topics of late, but there are also Model Organism Sharing, Research Tool, and other policies that may also apply. See [Which Policies Apply to My Research?](#)

### **Data Management and Sharing Plan**

- Required for all applications submitted to [funding opportunities subject to the NIH Data Management and Sharing Policy](#)
- Use new “Other Plan(s)” attachment field on PHS 398 Research Plan or PHS 398 Career Development Supplemental Form
- Address data management and sharing
- Address genomic data sharing (GDS) policy expectations when applicable
- Respond to any NIH Institute and Center or program-specific expectations related to data sharing outlined in the specific funding opportunity

### **Resource Sharing Plan**

- Not always required
- Use Resource Sharing Plan Attachment field on PHS 398 Research Plan, PHS 398 Career Development Supplemental Form, or PHS Fellowship Supplemental Form
- Address other applicable NIH-wide sharing policies (e.g., Model Organism Sharing Policy, Research Tools Policy)
  - For example, if you create a new model organism as part of your research, a Resource Sharing Plan must be submitted.
- Respond to any NIH Institute and Center or program-specific expectations related to non-data resources (e.g., software sharing) outlined in the specific funding opportunity

Please refer to the application instructions on the [How to Apply – Application Guide](#) page and the funding opportunity for additional requirements.

More information on NIH sharing policies can be found on the [NIH scientific data sharing site](#).

## GENERAL NOTICE

### NOTICE OF SPECIAL INTERESTS

If you will be applying under any of the special interest topics listed below, please indicate so, including the NIH Notice number, in the Comments box of the RAS Questionnaire. The RAS staff will ensure that this information is included with the application to NIH.

#### [NOT-CA-23-037](#) – **Technology Development for Cancer Control and Population Science Research**

The purpose of this Notice is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population scale -omics research with the goal of driving innovation in this field. This Notice applies to due dates on or after **March 1, 2023**, and subsequent receipt dates through **December 31, 2024**.

#### [NOT-HD-23-003](#) – **Research to Improve Pre-Pregnancy Care and Enhance Healthy Birth Intervals**

The purpose of this NOSI is to encourage research on the processes that facilitate or hinder the achievement of healthy interbirth intervals and promote healthy birth outcomes. This NOSI invites research applications that assess the causal social and behavioral processes that facilitate or hinder the achievement of healthy interbirth intervals and to identify mechanisms that can be modified by public health interventions at the levels of the dyad, family, community, or other population aggregates. This Notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **May 8, 2024**.

#### [NOT-DA-24-001](#) – **Pharmacogenomic Approaches to Enhancing HIV and Substance Use Disorder (SUD) Treatment Strategies, A jump into Precision Medicine**

NIDA is interested in receiving research proposals focusing on studying pharmacogenomics in PLWH with SUD as a crucial step in the science of Precision Medicine, in the path of personalized care for HIV and drug abuse. This Notice applies to due dates on or after **June 5, 2023**, and receipt dates through **May 8, 2026**.

#### [NOT-MD-23-002](#) – **Addressing the Etiology of Health Disparities and Health Advantages Among Immigrant Populations**

The purpose of the immigrant health initiative is to support innovative research to understand factors uniquely associated with the immigration experience that contribute to health disparities or health advantages among U.S. immigrant populations. This notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **June 8, 2026**.

#### [NOT-MD-23-003](#) – **Addressing Health Disparities Among Immigrant Populations Through Effective Interventions**

The purpose of the immigrant health initiative is to support research to design and implement effective interventions to enhance health advantages and reduce health disparities among U.S. immigrant populations (particularly agricultural workers, unaccompanied minors, first generation immigrants, and children of immigrant families) and address factors related to immigration experiences that affect health. This notice applies to due dates on or after **June 5, 2023**, and receipt dates through **June 8, 2026**.

#### [NOT-MD-23-008](#) – **Research to Address Vaccine Uptake and Implementation among Populations Experiencing Health Disparities**

The purpose of this NOSI is to solicit research that will: 1) understand and address barriers to increasing reach, access, and uptake of vaccinations among populations experiencing health disparities; 2) evaluate organizational, local, state, and federal policies and initiatives that mitigate or exacerbate disparities in vaccine access, uptake, and series completion, and 3) evaluate community-engaged interventions (e.g., expand reach, address psychosocial barriers, and social determinants of health [SDOH]) to facilitate vaccination uptake in clinical and community contexts. This notice applies to due dates on or after **May 17, 2023**, and subsequent receipt dates through **June 5, 2026**.

#### [NOT-AA-23-003](#) – **Advancing mHealth Interventions for Understanding and Preventing Alcohol-Related Domestic Violence**

The purpose of this solicitation is to announce NIAAA's interest in addressing the critical need for research

related to developing, testing, and intervening proximal to drinking occasions, when risk of DV is elevated, to decrease the likelihood of alcohol consumption at levels sufficient to trigger DV and to provide skills shown to reduce risk of DV perpetration and victimization. This notice applies to due dates on or after **June 5, 2023**, and subsequent receipt dates through **September 8, 2026**.

## NIH Funding Opportunities

### NIH Funding Opportunities: Request for Applications (RFA)

[RFA-OD-23-015](#) – (R01 Clinical Trial Optional)

#### **Revision Applications to Support Research on Prevention and Cessation of Menthol Cigarette Use in Populations that Experience Health Disparities**

As part of the ADVANCE: Advancing Prevention Research for Health Equity program, the NIH Office of Disease Prevention (ODP) within the Office of the Director Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI) is soliciting revision applications (formerly called "competitive revisions") to active R01 grants to support studies that develop and evaluate menthol cigarette smoking cessation and prevention interventions for populations that experience health disparities. **Application Due Date:** June 19, 2023. **Expiration Date:** June 20, 2023.

### JULY 2023 DUE DATES

[RFA-CA-23-025](#) – (U01 Clinical Trial Required)

#### **Addressing the Primary Care Needs of Cancer Survivors**

The purpose of this Funding Opportunity Announcement (FOA) is to support the development and testing of primary care practice (PCP)- and health system-level interventions and strategies to promote high quality care for adult cancer survivors during and/or after cancer treatment. The overall goal of this opportunity is to support high quality care for cancer survivors that integrates primary care from the point of diagnosis forward. **Application Due Date:** June 30, 2023. **Expiration Date:** July 1, 2023.

### AUGUST 2023 DUE DATES

[RFA-DA-24-013](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-014](#) – (R21 Clinical Trials Not Allowed)

#### **Mechanisms and Targets at the Intersection of HIV and Substance Use**

The purpose of this FOA is to support research on the discovery and development of novel chemical and biological approaches to prevent and/or treat central nervous system (CNS) complications associated with HIV infection and substance use. **Letter of Intent Due Date** – July 9, 2023. **Application Due Date:** August 9, 2023.

[RFA-MD-23-004](#) – (R01 – Clinical Trial Optional)

#### **Community Level Interventions to Improve Minority Health and Reduce Health Disparities**

This opportunity will support research projects to develop and test prospective community-level interventions to improve minority health and decrease health disparities. The initiative will emphasize research priorities that can be addressed through community-engaged research approaches and that utilize the [NIMHD Research Framework](#) to assess and intervene on health determinants beyond the individual level, at the interpersonal, family, organizational, neighborhood, community, and societal levels. **Application Due Dates:** July 7, 2023; *AIDS* – August 9, 2023. **Expiration Date:** August 10, 2023.

[RFA-DA-24-008](#) – (R01 Clinical Trials Not Allowed)

[RFA-DA-24-009](#) – (R21 Clinical Trials Not Allowed)

#### **Leveraging Big Data Science to Elucidate the Mechanisms of HIV Activity and Interaction with Substance Use Disorder**

The purpose of this FOA is to encourage research using data science and computational approaches to generate new insights into mechanisms and consequences of the interaction of HIV and addictive drugs. **Letter of Intent Due Date** – July 10, 2023. **Application Due Date:** August 10, 2023. **Expiration Date:** August 11, 2023.



[RFA-RM-23-005](#) – (DP2 clinical Trial Optional)

**NIH Director's New Innovator Award Program**

The NIH Director's New Innovator Award Program supports early-stage investigators of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications are sought which reflect the full diversity of the research workforce. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. **Application Due Date:** August 18, 2023. **Expiration Date:** August 19, 2023.

**SEPTEMBER 2023 DUE DATES**

[RFA-RM-23-006](#) – (R01 Clinical Trial Optional)

**NIH Director's Transformative Research Awards**

The NIH Director's Transformative Research Award Program supports individual scientists or groups of scientists proposing groundbreaking, exceptionally innovative, original, and/or unconventional research with the potential to create new scientific paradigms, establish entirely new and improved clinical approaches, or develop transformative technologies. Applications are welcome that are relevant to the broad mission of NIH, including, but not limited to, behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. No preliminary data are required. **Application Due Date:** September 1, 2023. **Expiration Date:** September 2, 2023.

[RFA-RM-23-007](#) – (DP5 Clinical Trial)

**NIH Director's Early Independence Awards**

The NIH Director's Early Independence Award supports rigorous and promising junior investigators who wish to pursue independent research soon after completion of their terminal doctoral degree or post-graduate clinical training, thereby forgoing the traditional post-doctoral training period and accelerating their entry into an independent research career. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. **Application Due Date:** September 6, 2023. **Expiration Date:** September 7, 2023.

[RFA-RM-23-004](#) – (DP1 Clinical Trial Optional)

**NIH Director's Pioneer Award Program**

The [NIH Director's Pioneer Award Program](#) supports individual scientists of exceptional creativity who propose highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH. Applications are sought which reflect the full diversity of the nation's research workforce. Applications in all topics relevant to the broad mission of NIH are welcome, including, but not limited to, topics in the behavioral, social, biomedical, applied, and formal sciences and topics that may involve basic, translational, or clinical research. To be considered pioneering, the proposed research must reflect substantially different scientific directions from those already being pursued in the investigator's research program or elsewhere. **Application Due Date:** September 8, 2023. **Expiration Date:** September 9, 2023.

**NOVEMBER 2023 DUE DATES**

[RFA-ES-23-007](#) – (P20 Clinical Trial Optional)

**Exploratory Grants for Climate Change and Health Research Center Development**

The purpose of this NOFO is to solicit P20 planning grant applications for Climate Change and Health Research Centers (CCHRCs). This program will support the development of an innovative research environment to foster and sustain a transdisciplinary program of fundamental and applied research to explore the complex impacts of climate change on health and to develop action-oriented strategies that protect health and build resiliency at the individual, community, national and global levels. **Application Due Date:** November 7, 2023. **Expiration Date:** November 8, 2023.

**MULTIPLE DUE DATES**

[RFA-CA-22-050](#) – (R01 Clinical Trial Optional)

**NCI Cancer Moonshot Scholars Diversity Program (CMSDP)**

The NCI, in alignment with NIH, continues to demonstrate a strong commitment to attracting, training, and

retaining the best minds from diverse backgrounds to ensure long-term successes in the cancer research enterprise. The overarching goal of the CMSDP is to increase the number of R01 Early Stage Investigators and enhance the diversity of the cancer research workforce, while promoting scientific advancements in cancer. Investigators from diverse backgrounds, including those from underrepresented groups ([NOT-OD-20-031](#), Notice of NIH's Interest in Diversity), are encouraged to work with their institutions to apply. **Application Due Dates:** June 6, 2023, February 6, 2024

[RFA-CA-23-014](#) – (R21 Clinical Trial Optional)

**Development of Innovation Informatics Methods and Algorithms for Cancer Research and Management**

The importance of this FOA is on supporting the development of novel informatics capabilities that involve a high degree of innovation and that have the potential to accelerate or enhance cancer research by inviting Exploratory/Developmental Research grant applications for innovative informatics methods and algorithms to improve the acquisition, analysis, visualization, or interpretation of data across the cancer research continuum.

**Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-CA-23-015](#) – (U01 Clinical Trial Optional)

**Early-Stage Development of Informatics Technologies for Cancer Research and Management**

This FOA focuses on early-stage development, defined here as initial tool development or the significant modification of an existing tool for a new cancer research application. The FOA encourages applications that involve the development of new, user-friendly informatics technologies that support a wide range of cancer research, including discovery biology, population studies, as well as clinical and translational research.

**Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-CA-23-016](#) – (U24 Clinical Trial Optional)

**Advanced Development of Informatics Technologies for Cancer Research and Management**

This FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. **Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-CA-23-017](#) – (U24 Clinical Trial Optional)

**Sustained Support for Informatics Technologies for Cancer Research and Management**

The purpose of this Announcement is to invite Cooperative Agreement applications for the continued development and sustainment of high-value informatics research resources to improve the acquisition, analysis, visualization, and interpretation of data across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. **Application Due Dates:** June 13, 2023, November 17, 2023

[RFA-HL-23-018](#) – (R21)

**Maximizing the Scientific Value of the NHLBI Biologic Biospecimen Repository: Scientific Opportunities for Exploratory Research**

This mechanism supports research relevant to the NHLBI mission ([Strategic Vision | NHLBI, NIH](#)) using the existing biospecimen collections that are stored in the Biorepository. Descriptions and access to the available biospecimen collections and associated datasets can be found at the NHLBI Biospecimen and Data Repository Information Coordinating Center (BioLINCC) website at [www.biolincc.nhlbi.nih.gov](http://www.biolincc.nhlbi.nih.gov).

**Application Due Dates:** June 20, 2023; October 19, 2023, June 20, 2024; and October 21, 2024

[RFA-OD-23-013](#) – (R21 Clinical Trial Optional)

[RFA-OD-23-014](#) – (R01 Clinical Trial Optional)

**Understanding Chronic Conditions Understudied Among Women**

The purpose of this Funding Opportunity is to invite R21 applications on chronic conditions understudied among women and/or that disproportionately affect populations of women who are understudied, underrepresented, and underreported in biomedical Research should align with Goal 1 of the [2019-2023 Trans-NIH Strategic Plan for Women's Health Research](#) "Advancing Science for the Health of Women." **Application Due Dates:** June 20, 2023; June 20, 2024

[RFA-DA-24-037](#) – (R21 Clinical Trial Optional)

**Accelerating the Pace of Drug Abuse Research Using Existing Data**

The purpose of this Announcement is to invite applications proposing innovative analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. **Application Due Dates:** August 9, 2023; November 15, 2023; March 4, 2024; August 5, 2024; and November 15, 2024

[RFA-HL-22-010](#) – (K01 Independent Clinical Trial Required)

[RFA-HL-22-011](#) – (K01 Independent Clinical Trial Not Allowed)

**Mentored Career Development Award to Promote Faculty Diversity in Biomedical Research**

This FOA invites applications to enhance the pool of highly trained investigators from diverse backgrounds, including those from groups underrepresented in research areas of interest to the NHLBI. It is targeted toward individuals whose basic, clinical, and translational research interests are grounded in the advanced methods and experimental approaches needed to solve problems related to cardiovascular, pulmonary, and hematologic diseases and sleep disorders in the general and health disparities populations.

**Application Due Dates:** October 13, 2023, February 13, 2024

[RFA-OD-22-023](#) – (K01 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-024](#) – (K01 – Independent Clinical Trial Required)

**Mentored Research Scientist Career Development Award in Tobacco Regulatory Research**

The purpose of the Mentored Research Scientist Career Development Award in Tobacco Regulatory Research is to provide support and protected time for an intensive, supervised career development experience in biomedical, behavioral, and social science research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing and that will lead to research independence. **Application Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-OD-22-025](#) – (K99/R00 – Independent Clinical Trial Not Allowed)

[RFA-OD-22-026](#) – (K99/R00 – Independent Clinical Trial Required)

**Pathway to Independence Award in Tobacco Regulatory Research**

The purpose of the Pathway to Independence Award in Tobacco Regulatory Research is to increase and maintain a strong cohort of new and talented independent investigators conducting research that will inform the development and evaluation of regulations on tobacco product manufacturing, distribution, and marketing.

**Application Due Dates:** November 14, 2023, July 12, 2024, March 12, 2025

[RFA-DA-23-013](#) – (R01 Clinical Trial Optional)

**NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes through Community-engaged Research**

This FOA seeks to fund innovative community partnered research by diverse teams that addresses community-driven priorities for reducing disparities in outcomes for racial and ethnic minority populations related to in substance use, addiction, and related health outcomes consequences, including HIV. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-061](#) – (R01 Clinical Trial Optional)

[RFA-DA-23-062](#) – (R34 Clinical Trial Optional)

**NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations**

The purpose of this FOA is to stimulate observational or intervention research on structural factors, organizational practices, policies, and other social, cultural, and contextual influences that lead to inequities at the intersection of HIV and substance use among underserved racial and/or ethnic minority populations affected by persistent HIV disparities. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-026](#) – (DP1 Clinical Trial Optional)

**NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity**

This announcement invites applications supporting independent, early career or established scholars who self-identify as health equity, health disparities, or social determinants of health experts with the skills to make exceptionally creative contributions to the study of equity for underserved U.S. racial and/or ethnic minority groups that experience poorer outcomes related to substance use and substance use disorders. This award supports transformative, boundary-pushing applications that may be risky or at a stage too early to fare well



in the traditional peer review process. **Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-028](#) – (R61/R33 Clinical Trial Optional)

**NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory**

This funding announcement invites exploratory mechanistic research seeking to parse the complex effects of structural racism and investigate its impact on neurocognition, with an emphasis on reducing SUD risk and informing preventative interventions. **Application Due Dates:** November 14, 2023, November 14, 2024

[RFA-DA-23-053](#) – (R61/R33 Clinical Trial Optional)

[RFA-DA-23-054](#) – (R33 Clinical Trial Optional)

**HEAL Initiative: Translating Research to Practice to End the Overdose Crisis**

This FOA solicits applications that address understudied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the individual, provider, organizational, community, or system levels. Projects should be in alignment with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the movement of evidence-based and promising treatments into routine use. **Due Dates:** November 15, 2023, March 20, 2024

[RFA-OD-22-028](#) – (R01 Clinical Trial Optional)

**The Intersection of Sex and Gender Influences on Health and Disease**

The purpose of this FOA is to invite applications on the influence and intersection of sex and gender in health and disease, including: (1) research applications that examine sex and gender factors and their intersection in understanding health and disease; and (2) research that addresses one of the five objectives from Strategic Goal 1 of the 2019-2023 [Trans-NIH Strategic Plan for Women's Health Research](#). **Application Due Dates:** November 22, 2023, November 22, 2024

[RFA-HL-23-004](#) – (R35, Clinical Trial Optional)

**NHLBI Outstanding Investigator Award (OIA)**

This award provides long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/Pis on at least two NHLBI R01-equivalent awards. The OIA supports a research program, rather than a research project, by providing the primary and most likely sole source of NHLBI funding on individual grant awards. **Application Due Dates:** February 15, 2024

[RFA-HL-23-005](#) – (R35, Clinical Trial Optional)

**NHLBI Emerging Investigator Award (EIA)**

The purpose of this award is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators who are currently PD/Pis on at least two NHLBI R01-equivalent awards. **Application Due Dates:** February 15, 2024

[RFA-DA-22-040](#) – (R01, Clinical Trial Optional)

**High Priority HIV and Substance Use Research**

This FOA supports high priority research at the intersection of HIV and substance use and invites innovative research projects with the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment and cure of HIV among people who use drugs (PWUD). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** February 16, 2024

[RFA-CA-22-045](#) – (R35 Clinical Trial Optional)

**NCI Outstanding Investigator Award**

The Outstanding Investigator Award is based on the accomplishments of the applicant. It is meant to support the cancer research program of individual scientists of exceptional creativity, demonstrated outstanding research accomplishments, and seminal past contributions in cancer research. For this FOA, the research strategy is expected to evolve over the seven-year award period. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 8, 2024

[RFA-DA-23-008](#) – (R61/R33, Clinical Trial Required)

**Stimulants and HIV: Addressing Contemporary and Recurring Epidemics**

The primary goal of this FOA is to support research to improve HIV prevention and care outcomes among people who use stimulants, encompassing a range of stimulant use (from episodic to persistent, methamphetamine and cocaine derivatives), including stimulant use co-occurring with the use of opioids and/or other drugs. **Application Due Dates:** Multiple Dates. **Expiration Date:** November 13, 2024

[RFA-DA-22-037](#) – (R01, Clinical Trial Optional)

[RFA-DA-22-038](#) – (R21, Clinical Trial Optional)

**Accelerating the Pace of Drug Abuse Research Using Existing Data**

This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV.

**Application Receipt Dates:** Multiple dates, see announcement. **Expiration Date:** November 16, 2024

[RFA-DA-23-021](#) – (R43/R44, Clinical Trial Optional)

**Developing Regulated Therapeutic and Diagnostic Solutions for Patients Affected by Opioid and/or Stimulants use Disorders (OUD/StUD)**

This FOA encourages SBIR grant applications directed towards commercialization, for the development of novel, evidence-based, FDA-regulated medical products addressing the needs of patients suffering from opioid use disorders and/or stimulant use disorders. **Due Dates:** Multiple Dates. **Expires:** February 15, 2025

[RFA-NS-22-022](#) – (K99/R00 Independent Clinical Trial Not Allowed)

[RFA-NS-22-023](#) – (Independent Basis Experimental Studies with Humans Required)

**HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAID and SUD Research**

The purpose of this Announcement is to assist eligible postdoctoral researchers in research areas supported by the NIH HEAL Initiative®, with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** March 12, 2025

[RFA-NS-22-024](#) – (K99/R00 Independent Basic Experimental Studies with Humans Required)

[RFA-NS-22-025](#) – (K99/R00 Independent Clinical Trial Not Allowed)

**HEAL Initiative Advanced Postdoctoral-to-Independent Career Transition Award in PAIN and SUD Research to Promote Diversity**

The purpose of this FOA is to assist a cohort of new and talented independent investigators from diverse backgrounds (e.g. see [NOT-OD-20-031](#) Notice of NIH's Interest in Diversity) with their transition to tenure-track or equivalent faculty positions and establishment of independent research programs in Pain and SUD research. Applications appropriate for this FOA may propose biomedical research across the spectrum of Pain and SUD research areas. **Application Due Dates:** Multiple Dates. **Expiration Date:** March 12, 2025

[RFA-ES-23-004](#) – (R21 Clinical Trial Not Allowed)

**Time-Sensitive Research Opportunities in Environmental Health Sciences**

This FOA is intended to support research in environmental health science in which an event has or will imminently occur that provides a limited window of opportunity to collect samples and data to support the assessment of exposures and human health impact. **Due Dates:** Multiple Dates. **Expires:** Dec. 2, 2025

**NIH Funding Opportunities: Program Announcements Reviews in an Institute (PAR)**

[PAR-23-083](#) – (R61 Clinical Trial Optional)

**Pilot Studies for the Spectrum of Alzheimer's Disease/Alzheimer's Disease-Related Dementias and Age-Related Cognitive Decline**

This FOA invites research grant applications that enable the collection of *pilot data* to support early stage testing of promising pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/ADRD across the spectrum from pre-symptomatic to more severe stages of disease. The goal of these pilot data is to serve as preliminary data for applications to the early stage and late stage clinical trial [PAR-23-081](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** November 19, 2024

[PAR-23-081](#) – (R01 Clinical Trial Optional)

**Early and Late-Stage Clinical Trials for the Spectrum of Alzheimer's Disease/Alzheimer's Related Dementias and Age-Related Cognitive Decline**

This FOA invites research grant applications that enable the early- to late-stage testing of promising

pharmacological and non-pharmacological interventions that target deleterious cognitive and neuropsychiatric changes associated with age-related cognitive decline and AD/DRD across the spectrum from pre-symptomatic to more severe stages of disease. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2025

[PAR-23-116](#) – (P30 Clinical Trial Not Allowed)

#### **Centers for AIDS Research**

The purpose of this FOA is to invite applications for the Centers for AIDS Research (CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. The program emphasizes interdisciplinary collaboration across all areas of HIV/AIDS research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** August 5, 2025

[PAR-23-117](#) – (P30 Clinical Trial Not Allowed)

#### **Developmental Centers for AIDS Research**

The FOA is to invite applications for the Developmental Centers for AIDS Research (D-CFAR) program to provide administrative and shared research support to enhance HIV/AIDS research. D-CFARs provide core facilities, expertise, resources, and services not readily obtained otherwise through more traditional funding mechanisms. Additionally, D-CFARs provide support to assist investigators in the development of a competitive standard CFAR. **Application Due Dates:** Multiple Dates. **Expiration Date:** August 5, 2025

[PAR-23-269](#) – (DP1 Clinical Trial Optional)

#### **NIDA Avant-Garde Program for IV and Substance Use Disorder Research**

Applications responding to this FOA must propose projects that align with the high priority HIV/AIDS research areas as described in [NOT-OD-20-018](#). Areas of interest include innovative basic, clinical or translational research that may lead to improved preventive interventions or therapies; creative strategies to prevent HIV transmission; novel approaches to improve outcomes of HIV and HIV-related comorbidities; innovative ideas to improve health outcomes of people with SUD and are living with HIV; and cutting-edge approaches to eradicating HIV. **Application Due Dates:** Multiple Dates. **Expiration Date:** August 15, 2025

[PAR-23-125](#) – (DP2 Clinical Trial Optional)

#### **Avenir Award Program for Research on Substance Use Disorders and HIV**

This Avenir program looks towards the future by supporting early stage investigators (ESI) proposing highly innovative studies at the nexus of substance use disorders (SUD) and HIV. This FOA aims to support broad spectrum of approaches spanning both basic and clinical research that have the potential to benefit substance using populations with or at risk for HIV. **Due Dates:** Multiple Dates. **Expires:** August 16, 2025

[PAR-23-055](#) – (R01 Clinical Trial Not Allowed)

[PAR-23-056](#) – (R21 Clinical Trial Not Allowed)

#### **Co-infection and Cancer**

This FOA is to enhance mechanistic and epidemiologic investigations addressing the roles of co-infection and cancer to shed light on presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** R01 – October 5, 2025; R21 – October 16, 2025

[PAR-23-072](#) – (R13 Clinical Trial Not Allowed)

#### **FDA Support for Conferences and Scientific Meetings**

The purpose of the FDA Scientific Conference Grant Program is to facilitate the provision of federal financial assistance in support of high-quality conferences and scientific meetings designed to research and investigate a topic clearly aligned with the FDA mission. *A Letter of Intent requesting advanced permission to submit a conference application is required and must be received via e-mail no later than eight (8) weeks prior to the selected application due date.* **Due Dates:** Multiple Dates. **Expires:** October 11, 2025

[PAR-23-051](#) – (U01 Clinical Trial Not Allowed)

[PAR-23-052](#) – (UH2 Clinical Trial Not Allowed)

#### **Mechanistic links between diet, lipid metabolism, and tumor growth and progression**

The purpose of this funding opportunity announcement is to request applications that propose mechanistic investigations of the links between diet, lipid metabolism and tumor growth and progression. It is anticipated that this program will support fundamental studies designed to identify and define the molecular mechanisms

through which lipid metabolism mediates tumor growth and progression, focusing specifically on the central role lipids play in linking diet with the biology of cancer; bridge the historically divided fields of nutrition and molecular metabolism; and stimulate research and tool development in this emerging area, which faces particular challenges because of the complexity of lipid biochemistry. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** October 24, 2025

[PAR-23-076](#) – P50 Clinical Trial Optional)

#### **NIDA Research Center of Excellence Grant Program**

This FOA is to provide support for research Centers that (1) conduct substance use and addiction research in any area of NIDA's mission, including the intersection of substance use/addiction and HIV, (2) foster outstanding innovative science, (3) are multidisciplinary, thematically integrated, synergistic, and (4) serve as national resource(s) to provide educational and outreach activities to relevant research communities, educational organizations, the general public, and policy makers. **Application Due Dates:** Multiple dates; see announcement. **Expiration Date:** November 19, 2025

[PAR-23-053](#) – (R61/R33 – Clinical Trial Optional)

#### **Research Infrastructure Development for Interdisciplinary Aging Studies**

This FOA invites applications that propose to develop novel research infrastructure that will advance the science of aging in specific areas requiring interdisciplinary partnerships or collaborations. Applications should propose the development of research infrastructure to advance specific topics in aging science that require interdisciplinary partnerships or collaborations. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** December 3, 2025

[PAR-23-058](#) – (R03 Clinical Trial Optional)

#### **NCI Small Grants Program for cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus)**

This funding opportunity supports small research projects on cancer that can be carried out in a short period of time with limited resources. This grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-034](#) – (R01 Clinical Trial Optional)

#### **NLM Research Grants in Biomedical Informatics and Data Science**

This funding opportunity focuses on biomedical discovery and data-powered health, integrating streams of complex and interconnected research outputs that can be translated into scientific insights, clinical care, public health practices, and personal wellness. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-036](#) – (R21 Clinical Trial Not Allowed)

#### **Secondary Analysis of Existing Datasets in Heart, Lung, and Blood Diseases and Sleep Disorders**

This FOA encourages applications that propose to conduct secondary analyses using existing human datasets in areas relevant to the National Heart, Lung, Blood Diseases and Sleep Disorders Institute (NHLBI) scientific mission. The FOA aims to stimulate the use of existing human datasets to investigate novel scientific ideas, and/or generate new models, systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-057](#) – (R01 Clinical Trial Required)

#### **NIA Multi-site Clinical Trial Implementation Grant**

This FOA invites applications for implementation of investigator-initiated multi-site interventional clinical trials (all phases). The trials should be hypothesis-driven, milestone-defined, and related to NIA's research mission. Information about NIA's mission can be found on the [NIA website](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-064](#) – (P01 Clinical Trial Optional)

#### **NIDA Program Project Grant Applications**

NIDA seeks collaborative research by multi-disciplinary teams to address critical issues of neuroscience, genetics, behavior, prevention, treatment, epidemiology, etiology, medications development, health services, HIV/AIDS and co-occurring opportunistic infections (e.g., viral hepatitis C, tuberculosis, sexually transmitted

infections) and associated consequences in people who use or misuse substances or have a substance use disorder, or other research areas relevant to substance use, misuse, or use disorders. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-112](#) – (R01 – Clinical Trial Optional)

**Addressing the Impact of Structural racism and Discrimination on Minority Health and Health Disparities**

This initiative will support intervention research that addresses structural racism and discrimination (SRD) in order to improve minority health or reduce health disparities. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** January 8, 2026

[PAR-23-060](#) – (R34 Clinical Trial Optional)

**Formative and Pilot Intervention research to Optimize HIV Prevention and Care Continuum Outcomes**

[PAR-23-061](#) – (R21 Clinical Trial Optional)

[PAR-23-062](#) – (R01 Clinical Trial Optional)

**Innovations to Optimize HIV Prevention and Care Continuum Outcomes**

The NIMH invites applications for Research Project Grants that propose formative research, intervention development, and pilot-testing of interventions; formative implementation research to inform adaptation of evidence-based interventions; or development or selection of implementation strategies. Primary scientific areas of focus include the feasibility, acceptability, and safety of novel or adapted interventions that target HIV prevention or treatment, or implementation outcomes using implementation science approaches. Applications with preliminary data and/or those including longitudinal analysis, advanced modeling, or large-scale clinical trials or implementation science approaches should consider using the companion R01 mechanism, PAR-23-062. If proposing to conduct exploratory, novel studies that break new ground, extend previous discoveries in new directions or result in novel techniques, models, applications should consider the R21 mechanism (PAR-23-061). **Application Due Dates:** Multiple Dates. **Expires:** January 10, 2026

[PAR-23-077](#) – (RM1 – Clinical Trial Optional)

**Collaborative Program Grant for Multidisciplinary Teams**

This Announcement encourages Collaborative Program Grant applications from institutions/organizations that propose projects addressing complex and challenging biomedical problems within the mission of NIGMS. **Application Due Dates:** Multiple Dates, see announcement. **Expiration Date:** January 28, 2026

[PAR-23-037](#) – (U01 Clinical Trial Optional)

**Multisite Clinical Research: Leveraging Network Infrastructure to Advance Research for Women, Children, Pregnant and Lactating Individuals, and Persons with Disabilities**

The purpose of this FOA is to invite applications for multisite clinical trials and large scale observational studies developed in conjunction with NICHD Networks that will be conducted using NICHD-supported Network infrastructure. The goal of this FOA is to operationalize the previously reported NICHD guiding principles for multisite clinical trials delineated in Notice [NOT-HD-19-034](#). **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-111](#) – (R21 – Clinical Trial Optional)

**NIMHD Exploratory/Developmental Research Grant Program**

NIMHD invites applications to support short-term exploratory or developmental research projects that have the potential to break new ground in the fields of minority health and/or health disparities or extend previous discoveries toward new directions or applications that can directly contribute to improving minority health and/or reducing health disparities in the U.S. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-122](#) – (R01 Clinical Trial Optional)

**Research With Activities Related to Diversity (ReWARD)**

The goal of the NIH ReWARD program is to enhance the breadth and geographical location of research and research-related activities supported by NIH. The ReWARD program provides support for the health-related research of scientists who are making a significant contribution to Diversity, Equity, Inclusion, and Accessibility (DEIA) and who have no current NIH research project grant funding. The grant will support scientific research in areas related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) and ongoing DEIA activities focused on enhancing diversity in the biomedical research enterprise within the United States and territories. **Application Due Dates:** Multiple Dates; see announcement. **Expiration**



**Date:** May 8, 2026

[PAR-23-152](#) – (R21 Clinical Trial Optional)

[PAR-23-153](#) – (R01 Clinical Trial Optional)

**Impacts of climate change across the cancer control continuum**

This Notice aims to support innovative research relevant to advancing the understanding of the effects of climate change across the cancer control continuum, from cancer etiology and cancer risks through survivorship, and ways to prevent or mitigate negative health effects. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

[PAR-23-155](#) – (R01 Clinical Trial Required)

**Understanding Expectancies in cancer Symptom Management**

This NOFO is intended to support mechanistic research that aims to understand how and why expectancy effects occur in a cancer context, elucidate their role in cancer symptom management, and identify patients, symptoms, cancer sites, and contexts in which expectancy effects can be leveraged to improve cancer outcomes. **Application Due Dates:** Multiple Dates; see announcement. **Expiration Date:** May 8, 2026

## University at Buffalo Funding Opportunities

**UB's Translational Pilot Studies Program** has released its [Spring 2023 Pilot Studies RFP](#). The program seeks proposals for innovative, high-impact clinical-translational science projects that will turn observations in the laboratory, clinic or community into interventions that improve the health of individuals/populations. Letters of Intent are due **May 15<sup>th</sup> by 9:00 am**. An information session will be held via Zoom on May 1<sup>st</sup> at 11 am. Register for the session [here](#).

### Words to Live By

*“Enjoy life. It's later than you think.”* – Muhammad Ali

For more information on RAS services, visit our website at [sphhp.buffalo.edu/ras](https://sphhp.buffalo.edu/ras)